Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 6/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9292329 | 0.85 | CYP3A4 (0.51) | SMN1; SMN2PKMCYP3A4CYP2C19NPSR1 | |
| SCHEMBL1035975 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2PKMCYP3A4CYP2C19NPSR1 | |
| SCHEMBL9879144 | 0.82 | PKM (0.50) | SMN1; SMN2PKMCYP3A4CYP2C19NPSR1 | |
| SCHEMBL5323999 | 0.82 | GABBR2 (0.57) | SMN1; SMN2PKMCYP3A4CYP2C19NPSR1 | |
| SCHEMBL27579705 | 0.81 | PKM (0.48) | SMN1; SMN2PKMCYP3A4CYP2C19NPSR1 | |
| SCHEMBL28110882 | 0.81 | CYP2C19 (0.50) | SMN1; SMN2PKMCYP3A4CYP2C19NPSR1 | |
| SCHEMBL16847573 | 0.80 | CYP3A4 (0.36) | SMN1; SMN2PKMCYP3A4NPSR1ALDH1A1 | |
| SCHEMBL7668299 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2PKMCYP3A4NPSR1ALDH1A1 | |
| SCHEMBL28812097 | 0.79 | NPSR1 (0.47) | SMN1; SMN2PKMCYP3A4NPSR1ALDH1A1 | |
| SCHEMBL1138729 | 0.79 | ALDH1A1 (0.51) | SMN1; SMN2CYP3A4CYP2C19ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348357-B2 | bactericide; derivatives of pseudopeptide Andrimid in which beta-phenylalanine amide is replaced by heteroaromatic or substituted aromatic amide; N-{(1S)-3-[((1S)-1-{[(3R,4S)-1,4-Dimethyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}-2-methylpropyl)amino]-3-oxo-1-phenylpropyl}-2-pyridinecarboxamide; antibiotics | BAYER HEALTHCARE AG (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20060173040-A1 | Arylamides | BAYER HEALTHCARE AG (DE) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173040-A1 | Arylamides | AADAC, AHR, ARSA | SMN1; SMN2 2406/4885PKM 3650/4885CYP3A4 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.